“…Possibly due to different inflammatory pathways involved, biologics in particular show different effects on bone, joint and skin lesions in SAPHO [20,32], whereby the exact extent of their effect is uncertain [33]. The tumour necrosis factor blockers, JAK inhibitors, and interleukin-1 and -17 inhibitors, which are selected and adapted according to the clinical picture, are of greatest importance [32].…”